Michelle Burke joins AusBiotech board
01 November, 2012 by Tim DeanPharmaceutical industry and policy expert, Michelle Burke, has joined the AusBiotech board, as Dr Paul Walton and Dr Peter Isdale AM depart.
Patrys cleared to extend myeloma trial
01 November, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has secured ethics approval to add an Australian site to its planned phase I/IIa trial of cancer drug candidate PAB-SM6 for multiple myeloma.
Medical investment today like funding mining exploration and building no mines: investor
01 November, 2012 by Tim DeanThe disparity between money invested in medical discoveries compared to commercialisation is akin to investing in mining exploration and nothing else, says Dr Jurgen Michaelis, Executive Director of newly launched Verde Capital, a venture capital fund.
AusBiotech 2012: The real ‘valley of death’ is dealing with regulators: Alan Robertson
01 November, 2012 by Tim DeanThe gap between applying for marketing approval and receiving the go-ahead from regulators is the real ‘valley of death’ facing biotechs, says Alan Robertson, CEO of Pharmaxis.
Day of Awards at AusBiotech 2012
01 November, 2012 by AusBiotechStarpharma, Vaxxas, Dr Andrew Baker and Connor O’Meara all received awards at the AusBiotech 2012 conference in Melbourne last night.
AusBiotech 2012: Future of health care depends on reforming regulators
31 October, 2012 by Tim DeanHealth regulators need a radical overhaul if the “innovation gap” between research and health care is to be bridged in the future, says Dr Richard Barker.
Phosphagenics forms horse supplement JV
31 October, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has formed a joint venture with a subsidiary of Equine Nutrition Australia to market a line of horse supplements using its TPM delivery technology.
Octa Phillip loses fight for Bioxyne
31 October, 2012 by Dylan Bushell-EmblingShareholders in Bioxyne (ASX:BXN) resisted a call by investor group Octa Phillip to remove several directors and cease development of HI 164, instead voting to remove Octa's own MD from the board.
Starpharma technology gives glyphosate a boost
31 October, 2012 by Dylan Bushell-EmblingStarpharma (ASX:SPL) said agrochemicals produced using its dendrimer program were more effective and rain-resistant than the original formulas during laboratory trials.
GI Dynamics to start pivotal US trial of EndoBarrier
31 October, 2012 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has got the all-clear from the FDA to commence a 25-site pivotal trial of EndoBarrier in type 2 diabetes in the US.
Phosphagenics licenses TPM to Indian pharma
30 October, 2012 by Dylan Bushell-EmblingIndia's Agila Specialties has arranged to license Phosphagenics' (ASX:POH) TPM drug delivery platform, and use it to create an injectable antibiotic product.
AusBiotech 2012 special feature: Big deals
30 October, 2012 by Dylan Bushell-EmblingBe it through major licensing or development deals, domestic and international expansion, mergers and spin-offs or potentially game-changing research, biotechnology companies across Australia have been making waves in recent months.
AusFoodTech Symposium 2012 to feature Dr Andrew Powell
30 October, 2012 by AusBiotechThe second AusFoodtech symposium, to be held on Friday in Melbourne, will feature keynote speaker, Dr Andrew Powell, Chief Executive Officer of Asia BioBusiness.
Benitec completes Tacere acquisition
30 October, 2012 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has completed the acquisition of US-based RNA interference therapeutics discovery company Tacere Therapeutics.
Melbourne Uni cuts deal with Janssen-Cilag to research respiratory infection drug
29 October, 2012 by Dylan Bushell-EmblingThe University of Melbourne and Janssen-Cilag have signed a collaboration agreement covering research into drug candidates for acute respiratory infections.
